Neuro Bio

Executive Summary

Neuro Bio is a UK-based biotechnology company pioneering a novel approach to Alzheimer's disease based on the T14 peptide, which it identifies as a key upstream driver of neurodegeneration. Founded in 2013, the company is developing a pre-symptomatic diagnostic test and a therapeutic candidate, NBP-14, designed to neutralize T14 toxicity. This dual strategy positions Neuro Bio to address both early detection and intervention in Alzheimer's, a market with immense unmet need. The company's platform is differentiated by its focus on a specific pathological trigger rather than downstream amyloid or tau targets, potentially enabling earlier and more effective treatments. However, Neuro Bio remains in early development stages with no disclosed clinical trial data, and the company's financial position and regulatory path are not yet public. Success depends on validating the T14 mechanism in humans and advancing NBP-14 through clinical trials, which carries inherent scientific and regulatory risks. If successful, Neuro Bio's approach could redefine Alzheimer's treatment paradigms.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical efficacy studies for NBP-1460% success
• Q4 2026Initial validation data from pre-symptomatic biomarker test50% success
• Q2 2026Series A or strategic partnership announcement40% success